|
|
 |
 | Medical News Releases > Faculty Experts at Washington University in St. Louis >
Donald O. Schnuck Family Professor of Neurology
Expertise: Brain tumors, cancer genetics, neurofibromatosis, molecular genetics, neurosciences, neurology
Bio: Gutmann is the founder and director of the Neurofibromatosis Clinical Program, which is dedicated to treating the common inherited tumor predisposition syndrome, neurofibromatosis (NF). Individuals with NF have an increased risk of developing brain tumors and other cancers. As national leader in the development of genetically-modified mouse models of human cancers, he has developed mouse models of NF brain tumors. Lastly, using a team approach to translate basic science discoveries to improved clinical care for individuals with NF, Gutmann established the Washington University NF Center in 2004.
Education:
-
M.D. at University of Michigan
-
Ph.D. at University of Michigan
-
M.S. in Human genetics at University of Michigan
| News Stories & Tip Sheets: |
Showing Stories 1 through 10 of 14.
- Show Home
Show page:
1 | 2 | next |
|
New drug target
Mutation linked to pediatric brain tumor may pave way for targeted treatment
Oct. 29,
2009 -- Researchers at the School of Medicine have linked mutations in a gene to a benign pediatric brain tumor, a finding that will help scientists seek drug treatments that block growth of the tumors, they report in the journal Neurology.
|
Cancer: weapons and suspects
WUSTL leads study of pediatric brain tumors
Aug. 10,
2009 -- The National Cancer Institute (NCI) has awarded a five-year, $4 million grant to researchers at the School of Medicine to use genetically-engineered mice to study the origins and potential treatments of pediatric brain tumors. David H. Gutmann, the Donald O. Schnuck Family Professor of Neurology, is principal investigator of the grant, which is part of the NCI's Mouse Models of Human Cancers Consortium. He is also on staff at Barnes-Jewish and St. Louis Children's hospitals.
|
Brain tumors connected to molecular make-up of cells
Brain cells' hidden differences linked to potential cancer risk
Feb. 19,
2009 -- Brain cells long lumped into the same category have hidden differences that may contribute to the formation of tumors, according to a new study from researchers at the School of Medicine. Scientists showed that brain cells known as astrocytes make use of different genes depending on what region of the mouse brain they came from. These differences are too subtle to overtly mark them as distinct cell types, but substantial enough to make it easier for the cells to multiply more in response to genetic changes that increase cancer risk.
|
Surprising details about gene that affects height
Gene's newly explained effect on height may change tumor disorder treatment
Aug. 11,
2008 -- A mutation that causes a childhood tumor syndrome also impairs growth hormone secretion, researchers at the School of Medicine have found. The discovery provides new insights into an old mystery, revealing why patients with neurofibromatosis type 1 are frequently shorter than their peers. The surprising details have led scientists to consider modifying their search for treatments for the inherited disorder, which is caused by a mutation in the neurofibromin 1 (NF1) gene and is characterized by an increased risk of cancer.
|
Quicker translation from mouse to human
Mouse model tightly matches pediatric tumor syndrome, will speed drug hunt
March 1,
2008 -- Frustrated by the slow pace of new drug development for a condition that causes pediatric brain tumors, a neurologist at the School of Medicine decided to try to fine-tune the animal models used to test new drugs. Instead of studying one mouse model of the disease causing the brain tumors, the laboratory of David Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology, evaluated three and found that one of most closely mimicked what is seen in children who develop brain tumors.
|
Shaping young minds
Cancer gene drives pivotal decision in early brain development
Nov. 12,
2007 -- A gene linked to pediatric brain tumors is an essential driver of early brain development, researchers at the School of Medicine have found. The study, published in October in Cell Stem Cell, reveals that the neurofibromatosis 1 (NF1) gene helps push stem cells down separate paths that lead them to become two major types of brain cells: support cells known as astrocytes and brain neurons.
|
Tumor trick probed
Study suggests existing drugs may be useful in treating brain tumors
Oct. 15,
2007 -- Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication. Researchers at the School of Medicine found the transformation relies on at least two other molecules that can be modified with existing drugs, opening the possibility that they may be able to use the established drugs to treat brain tumors.
|
Slowing tumor growth
Brain tumors coax important support from nearby immune system cells
April 11,
2007 -- Developing brain tumors can coax assistance from nearby cells known as microglia, according to a new study from scientists at the School of Medicine. The researchers have identified one protein made by microglia that helps accelerate tumor growth and are looking for others.
|
Tumor bar code
Genetic fingerprints identify brain tumors' origins
Feb. 1,
2007 --
 |
| Gutmann |
Genetic fingerprints that reveal where a brain cell came from remain distinct even after the cell becomes a brain tumor, an international coalition of scientists will report in the February 1 issue of Cancer Research. The finding adds a new layer of complexity to the quest to understand the causes of childhood brain cancers, according to senior author David Gutmann.
|
Targeting tumors
New therapeutic target identified in inherited brain tumor disorder
Oct. 31,
2005 -- Researchers studying a mouse model of neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors, have found their second new drug target in a year, a protein called methionine aminopeptidase-2 (MetAP2).
|
Showing Stories 1 through 10 of 14.
- Show Home
Show page:
1 | 2 | next |
|
Affiliated with Barnes-Jewish Hospital and St. Louis Children's Hospital, members of BJC HealthCare.
Please contact us and let us know how we can assist you.
Technical problems with this Web site? Email questions or comments.
Please review the WUSTL News & Information copyright/privacy policy.
| |
|
| | |
|
Print ready page